Top 4 Small-Cap Stocks In The Diagnostic Substances Industry With The Highest Revenue Estimates

Below are the top small-cap diagnostic substances stocks on the NYSE and the NASDAQ in terms of revenue estimate for the current year. Neogen (NASDAQ: NEOG ) is likely to post revenue of $235.22 million in the year ending May, 2014. Neogen's PEG ratio is 2.85. Analysts expect Meridian Bioscience (NASDAQ: